Genscript Bio (01548) has announced that on August 20, 2026, it issued 1.129 million shares pursuant to the exercise of share options under the post-listing share option scheme adopted on December 7, 2015.
Additionally, the company issued a total of 5.6545 million new shares or transferred treasury shares in relation to share awards or options granted to directors of the issuer under the share scheme.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.